Genomics & Informatics

Korea Genome Organization (한국유전체학회)
권호 표지
DOI QR코드

DOI QR Code

Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOP

  • Kim, Min Kyeong (Department of System Cancer Science, Graduate School of Cancer Science and Policy) ;
  • Yoo, Kyong-Ah (Center for Breast Cancer, National Cancer Center) ;
  • Park, Eun Young (Biometric Research Branch, Division of Cancer Epidemiology and Prevention, National Cancer Center) ;
  • Joo, Jungnam (Biometric Research Branch, Division of Cancer Epidemiology and Prevention, National Cancer Center) ;
  • Lee, Eun Young (Center for Hematologic Malignancy, National Cancer Center) ;
  • Eom, Hyeon-Seok (Center for Hematologic Malignancy, National Cancer Center) ;
  • Kong, Sun-Young (Department of System Cancer Science, Graduate School of Cancer Science and Policy)
  • Received : 2016.08.01
  • Accepted : 2016.09.29
  • Published : 2016.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Interleukin-10 (IL10) plays an important role in initiating and maintaining an appropriate immune response to non-Hodgkin lymphoma (NHL). Previous studies have revealed that the transcription of IL10 mRNA and its protein expression may be infl uenced by several single-nucleotide polymorphisms in the promoter and intron regions, including rs1800896, rs1800871, and rs1800872. However, the impact of polymorphisms of the IL10 gene on NHL prognosis has not been fully elucidated. Here, we investigated the association between IL10 polymorphisms and NHL prognosis. This study involved 112 NHL patients treated at the National Cancer Center, Korea. The median age was 57 years, and 70 patients (62.5%) were men. Clinical characteristics, including age, performance status, stage, and extra-nodal involvement, as well as cell lineage and International Prognostic Index (IPI), were evaluated. A total of four polymorphisms in IL10 with heterozygous alleles were analyzed for hazard ratios of overall survival (OS) and progression-free survival (PFS) using Cox proportional hazards regression analysis. Diffuse large B-cell lymphoma was the most common histologic type (n = 83), followed by T-cell lymphoma (n = 18), mantle cell lymphoma (n = 6), and others (n = 5). Cell lineage, IPI, and extra-nodal involvement were predictors of prognosis. In the additive genetic model results for each IL10 polymorphism, the rs1800871 and rs1800872 polymorphisms represented a marginal association with OS (p = 0.09 and p = 0.06) and PFS (p = 0.05 and p = 0.08) in B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). These findings suggest that IL10 polymorphisms might be prognostic indicators for patients with B-cell NHL treated with R-CHOP.

Keywords

References

  1. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012;380:848-857. https://doi.org/10.1016/S0140-6736(12)60605-9
  2. Jung KW, Won YJ, Oh CM, Kong HJ, Cho H, Lee JK, et al. Prediction of cancer incidence and mortality in Korea, 2016. Cancer Res Treat 2016;48:451-457. https://doi.org/10.4143/crt.2016.092
  3. Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol 2010;11:827-834. https://doi.org/10.1016/S1470-2045(10)70167-4
  4. Micallef IN, Remstein ED, Ansell SM, Colgan JP, Inwards DJ, Johnston PB, et al. The International Prognostic Index predicts outcome after histological transformation of low-grade non- Hodgkin lymphoma. Leuk Lymphoma 2006;47:1794-1799. https://doi.org/10.1080/10428190600757894
  5. Rossi G, Donisi A, Casari S, Re A, Cadeo G, Carosi G. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma. Cancer 1999;86:2391-2397. https://doi.org/10.1002/(SICI)1097-0142(19991201)86:11<2391::AID-CNCR29>3.0.CO;2-0
  6. Khatri VP, Caligiuri MA. A review of the association between interleukin-10 and human B-cell malignancies. Cancer Immunol Immunother 1998;46:239-244. https://doi.org/10.1007/s002620050483
  7. Domingo-Domenech E, Benavente Y, Gonzalez-Barca E, Montalban C, Guma J, Bosch R, et al. Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms. Haematologica 2007;92:1475-1481. https://doi.org/10.3324/haematol.11350
  8. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8. https://doi.org/10.1111/j.1365-2370.1997.tb00001.x
  9. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: International Agency for Research on Cancer, 2008.
  10. Warnes G, Gorjanc G, Leisch F, Man M. 2013. Genetics: a package for population genetics. R Package (Version 1.3.8.1). R Foundation. Accessed 2016 Oct 1. Available from: http://www.r-project.org.
  11. Zhang Y, Xia ZG, Zhu JH, Chen MB, Wang TM, Shen WX, et al. Association of interleukin-10 -3575T>A and -1082A>G polymorphisms with non-Hodgkin lymphoma susceptibility: a comprehensive review and meta-analysis. Mol Genet Genomics 2015;290:2063-2073. https://doi.org/10.1007/s00438-015-1058-y
  12. Li G, Li D. Relationship between IL-10 gene polymorphisms and the risk of non-Hodgkin lymphoma: A meta-analysis. Hum Immunol 2016;77:418-425. https://doi.org/10.1016/j.humimm.2016.03.006
  13. Dai ZM, He AL, Zhang WG, Liu J, Cao XM, Chen YX, et al. Association of the four common polymorphisms in interleukin-10 (rs1800890, rs1800896, rs1800871, and rs1800872) with non-Hodgkin's lymphoma risk: a meta-analysis. Int J Clin Exp Med 2014;7:4720-4733.
  14. Lee JJ, Kim DH, Lee NY, Sohn SK, Kim JG, Kim HJ, et al. Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas. Br J Haematol 2007;137: 329-336. https://doi.org/10.1111/j.1365-2141.2007.06570.x
  15. Bogunia-Kubik K, Mazur G, Wrobel T, Kuliczkowski K, Lange A. Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma. Tissue Antigens 2008; 71:146-150. https://doi.org/10.1111/j.1399-0039.2007.00984.x
  16. Kube D, Hua TD, Kloss M, Kulle B, Brockmoller J, Wojnowski L, et al. The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma. Genes Immun 2007;8:164-167. https://doi.org/10.1038/sj.gene.6364364